According to Haizheng Pharmaceutical's announcement, Zhejiang Haizheng Animal Health Products Co., Ltd., a holding subsidiary of the company, has received an approval document for the compound nonprednisolone moxicidine drops veterinary drug product approved and issued by the Ministry of Agriculture and Rural Affairs. The approval number is valid from September 10, 2026 to September 9, 2031. This product is used to prevent and treat internal and external parasite infections in cats. This approval will enrich the company's product structure and promote the company's strategic layout in the pet medicine sector. There is uncertainty about product marketing and sales, so investors are kindly requested to pay attention to investment risks.

According to Haizheng Pharmaceutical's announcement, Zhejiang Haizheng Animal Health Products Co., Ltd., a holding subsidiary of the company, has received an approval document for the compound nonprednisolone moxicidine drops veterinary drug product approved and issued by the Ministry of Agriculture and Rural Affairs. The approval number is valid from September 10, 2026 to September 9, 2031. This product is used to prevent and treat internal and external parasite infections in cats. This approval will enrich the company's product structure and promote the company's strategic layout in the pet medicine sector. There is uncertainty about product marketing and sales, so investors are kindly requested to pay attention to investment risks.